Pall T. Onundarson on Correlation Between Plasma Levels of DOACs and Both Thromboembolic and Bleeding Events
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, shared on LinkedIn:
”In the May 2025 issue of JTH, Cosmo Godino and colleagues from Milan report a strong correlation between plasma levels of four DOACs and both thromboembolic and bleeding events.
Their findings reveal a U-shaped relationship, reminiscent of what older physicians recall from the warfarin era.
The authors conclude that monitoring DOAC levels and adjusting doses could improve outcomes for at least some patients.
When DOACs were introduced about 20 years ago, many in the thrombosis community were skeptical of the “no monitoring” strategy.
Nevertheless, manufacturers advanced this approach to emphasize the convenience of DOACs over low-cost, PT-monitored warfarin and other VKAs.
The new data suggest that outcomes with DOACs might improve if doses were tailored to individual patients – something current fixed tablet sizes largely prevent.
But tailoring of DOACs would effectively reintroduce the hallmarks of warfarin therapy: monitoring, dose adjustment by professionals, or self-management with point-of-care devices.
While such a shift might be beneficial, it would also add cost and inconvenience to DOAC use, potentially making warfarin more competitive again!
Importantly, warfarin monitoring and dosing has itself improved although rarely mentioned.
As an example, three clinical studies have shown that Fiix-monitored warfarin reduces thromboembolism by about 50%, along with reduced monitoring frequency and dose adjustments, compared with conventional PT-based warfarin management. Emerging evidence further suggests that Fiix-warfarin achieves similar outcome advantages when compared with apixaban, rivaroxaban, and dabigatran.
The next step must be be independent studies directly comparing tailored DOAC therapy against standard fixed-dose DOAC regimens and prefarably against the improved Fiix-monitored warfarin as well. The results could reshape how these drugs are positioned relative to warfarin.
In short: Bringing monitoring and improved dose tailoring back is good for patients.”
Stay updated on all scientific advances with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration